Results
- Showing results for:
- Reset all filters
Search results
-
Journal articleMcGovern H, Aqil M, Atasoy S, et al., 2025,
Eigenmodes of the deep unconscious: the neuropsychology of Jungian archetypes and psychedelic experience
, Neuroscience of Consciousness, Vol: 2025This article presents a neuroscientific interpretation of Carl Jung’s theory of archetypes and their experience in altered states of consciousness. We begin by rehearsing the Free Energy Principle and Predictive Processing as foundational frameworks that subserve and inform the thesis that follows. The following sections examine three aspects of archetypes: the affective core rooted in subcortical systems, archetypal imagery emergent in altered states such as psychedelic experiences, and archetypal stories encoded in higher cortical areas. Specifically, we propose a trilogical interplay between the high-level cortex, the low-level cortex, and subcortical/affective systems in instantiating these archetypal phenomena. We then explore how archetypes may be transmitted between individuals, developing into a collective unconscious through social learning and subsequent attunement. Throughout, we provide syntheses of Jungian psychology with contemporary neuroscience, offering testable hypotheses regarding the neurological bases of archetypal phenomena. We conclude by discussing implications for both psychoanalytic theory and neuroscientific research. By bridging these disciplines, we aim to lend construct validity to Jungian concepts and encourage further empirical investigation of archetypes and the collective unconscious.
-
Journal articleO'Connor S, Godfrey K, Reed S, et al., 2025,
Correction: Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.
, Cureus, Vol: 17, ISSN: 2168-8184[This corrects the article DOI: 10.7759/cureus.78171.].
-
Journal articleO'Connor S, Godfrey K, Reed S, et al., 2025,
Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.
, Cureus, Vol: 17, ISSN: 2168-8184BACKGROUND: Obsessive-compulsive disorder (OCD) is a complex condition marked by persistent distressing thoughts and repetitive behaviours. Despite its prevalence, the mechanisms behind OCD remain elusive, and current treatments are limited. This protocol outlines an investigative study for individuals with OCD, exploring the potential of psilocybin to improve key components of cognition implicated in the disorder. The PsilOCD study strives to assess the effects of low-moderate psilocybin treatment (10 mg) alongside non-interventional therapy on several facets of OCD. The main focus points of PsilOCD are cognitive flexibility, measured with cognitive tests, and neuroplasticity, assessed through electroencephalography (EEG). METHODS: 20 blinded participants with OCD will complete two dosing sessions, separated by four weeks, where they will receive 1 mg of psilocybin on the first and 10 mg on the second. The first dose serves as an active placebo, and the latter is a low-moderate dose that induces relatively mild-moderate emotional and perceptual effects. Participants will be supported by trained psychedelic therapists, who will sit with them during each dosing session and provide virtual preparation and integration sessions over the 12-week study period. Therapeutic support will be the same for both the 1 mg and 10 mg sessions. PsilOCD's primary outcomes include scores in the intradimensional-extradimensional (ID-ED) shift task, which is an established measure of cognitive flexibility, and neuroplasticity as quantified by a visual long-term potentiation (vLTP) task. This task is delivered as part of an EEG paradigm and measures acute quantified changes in neuroplasticity in the brain's visual system. The ID-ED task will be conducted twice, two days after each dosing session, and the EEG recordings will also be taken twice, immediately after each session. Secondary outcome assessments will include OCD and affective symptom severity, as well as an array of patien
-
Journal articleKettner H, Roseman L, Gazzaley A, et al., 2025,
Reply to Letter to the Editor: " Psychedelics in Older Adults: Difficulties of a Clear Therapeutic Evidence"
, AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, Vol: 33, Pages: 118-119, ISSN: 1064-7481 -
Journal articlePasquini L, Simon AJ, Gallen CL, et al., 2025,
Dynamic medial parietal and hippocampal deactivations under DMT relate to sympathetic output and altered sense of time, space, and the self
, Imaging neuroscience (Cambridge, Mass.), Vol: 3, ISSN: 2837-6056 -
Book chapterWall MB, Carhart-Harris RL, 2025,
Human neuroimaging: fMRI.
, Pages: 149-170Human neuroimaging with functional Magnetic Resonance Imaging has been a key feature of the current wave of psychedelic research, in both healthy and clinical populations. The available data has suggested that classic psychedelics (psilocybin, LSD, DMT) have a characteristic effect of acutely and profoundly disrupting the normal pattern of resting-state connectivity in the human brain, and that this effect may be closely related to both the characteristic subjective phenomenology of psychedelics, and their more clinically-relevant longer-term effects on emotional brain systems. This chapter briefly outlines the basic methodological background of fMRI, and then provides an overview of the current state of knowledge of psychedelic drug action as revealed by task and resting-state fMRI, in both non-clinical and clinical cohorts. Current limitations of the field are largely addressable by ongoing and future work, particularly in terms of providing additional datasets, increased standardisation of data acquisition and analysis procedures, potential multi-modal imaging studies, and more open data-sharing. Neuroimaging with fMRI remains a central platform of modern psychedelic research, with implications for our mechanistic understanding of psychedelics, as well as a strong influence on the clinical development of psychedelic-based treatments.
-
Journal articleHarding R, Ertl N, Zafar R, et al., 2025,
Effects of escitalopram and psilocybin therapy on mesolimbic resting-state functional connectivity in depression
, Neuroscience Applied, Vol: 4, Pages: 105421-105421, ISSN: 2772-4085 -
Book chapterGodfrey K, Luan LX, Timmermann C, 2025,
Effects of psychedelics on human oscillatory brain activity.
, Pages: 171-202This chapter reviews the effects of classic psychedelics on human oscillatory brain activity, as measured by resting-state electroencephalography (EEG) and magnetoencephalography (MEG). Across moderate to high doses of LSD, psilocybin, ayahuasca, and DMT, a consistent reduction in alpha power (8-13 Hz) emerges, particularly in occipital regions. Below 30 Hz, desynchronization is typical, although DMT can preserve or even increase delta/theta activity, possibly reflecting its immersive, immersive visual phenomenology. Complementing these spectral findings, measures of signal diversity (e.g., Lempel-Ziv complexity) reliably increase during psychedelic states, indicating a more variable and unpredictable pattern of neural firing. Retrospective subjective ratings of the psychedelic experience often fail to align consistently with M/EEG changes, possibly because fleeting, key experiences are obscured by data averaging or recording short segments of a long experience. In contrast, real-time evaluations of subjective intensity and plasma levels robustly covary with changes in spectral power and complexity, highlighting the potential for objective, real-time EEG biomarkers of drug activity. Limited research on functional connectivity and cortical travelling waves suggest that directed, top-down control may decrease while bottom-up signaling increases, indicating a transient reversal of typical hierarchical organization, though replications are warrented. Future work should implement more unified methodological approaches, alongside high-resolution behavioral sampling, to further our understanding of how these altered brain dynamics give rise to the distinctive qualities of the psychedelic experience. Notably, EEG has yet to be evaluated in clinical studies, and future work should aim to explore the relationship between acute EEG changes and clinical responses to psychedelic therapy.
-
Journal articleGodfrey K, Weiss B, Zhang X, et al., 2025,
An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers
, NEUROSCIENCE APPLIED, Vol: 4- Cite
- Citations: 1
-
Journal articleWingert AM, Agnorelli C, Peill J, et al., 2025,
Serotonergic psychedelics for depression: A comprehensive overview.
, Int Rev Neurobiol, Vol: 181, Pages: 271-304Depressive disorders continue to pose a major clinical challenge worldwide, particularly given the high prevalence and increasing number of treatment-resistant cases. Over the past decade, advances in research have elucidated the antidepressant potential of psilocybin and other 5-HT₂A receptor agonists in patients with major depressive disorder (MDD) and treatment-resistant depression (TRD). Phase I and II clinical trials have consistently demonstrated that even a single administration can yield rapid and sustained symptom reduction. These effects compare favourably with conventional pharmacotherapies such as SSRIs and ketamine. The distinctive pharmacological profile and robust safety data associated with serotonergic psychedelics make them particularly promising candidates, especially for patients who do not respond to standard treatments. Nonetheless, several challenges impede their integration into routine clinical practice, including the resource-intensive nature of psychedelic-assisted therapy, which demands specialized training and controlled settings. Despite those limitations, some countries including Australia, Switzerland or Canada are paving the way by allowing the use of psilocybin in TRD cases. This chapter reviews the antidepressant potential of psilocybin, DMT, ayahuasca and 5-MeO-DMT based on modern clinical trial data, comparing effect sizes of psychedelics to conventional treatments like SSRIs and ketamine, and provides a brief overview of their potential neurobiological mechanisms.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.
